Found: 6
Select item for more details and to access through your institution.
Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models.
- Published in:
- Journal of Personalized Medicine, 2020, v. 10, n. 4, p. 179, doi. 10.3390/jpm10040179
- By:
- Publication type:
- Article
The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients.
- Published in:
- Cancers, 2024, v. 16, n. 8, p. 1487, doi. 10.3390/cancers16081487
- By:
- Publication type:
- Article
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology.
- Published in:
- Cancers, 2023, v. 15, n. 5, p. 1397, doi. 10.3390/cancers15051397
- By:
- Publication type:
- Article
SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3316, doi. 10.3390/cancers12113316
- By:
- Publication type:
- Article
Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.680758
- By:
- Publication type:
- Article
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 20, p. 11299, doi. 10.3390/ijms252011299
- By:
- Publication type:
- Article